The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
Welcome to season 1 of the MDS Professional Report. We look forward to your feedback!
This podcast will discuss the combination of azacitidine and pembrolizumab in patients with higher-risk MDS, a personalized prediction model based on clinical and genomic data, the classification of therapy-related MDS as well as the importance of platelet counts as a prognostic factor.
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodysplastic syndromes. We will then report a study testing the efficacy and safety of imetelstat, a new telomerase-inhibitor, in the treatment of patients with lower-risk MDS and anemia following ESA failure.
Our host, Professor Moshe Mittelman from Tel-Aviv Sourasky Medical Center, will review 4 studies discussing if a COVID diagnosis should impact MDS treatments, therapeutic options for anemia and the use of pevonedistat with azacytidine in high-risk MDS.